Transmembrane AMPA receptor regulatory protein gamma-4 (TARP gamma-4)

Transmembrane AMPA receptor regulatory protein gamma-4 (TARP gamma-4), encoded by the CACNG4 gene, is a member of the Type I TARP family that critically regulates the trafficking and biophysical properties of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [1][2]. It is primarily expressed in the central nervous system, where it facilitates the delivery of AMPA receptors to the postsynaptic membrane and modulates their response to glutamate by slowing desensitization and deactivation [3]. By controlling the number and function of these receptors at synapses, TARP gamma-4 plays a vital role in synaptic plasticity and excitatory neurotransmission [2][4]. In pathological states, dysregulation of TARP gamma-4 is associated with neurological conditions such as epilepsy and chronic pain, making it an attractive target for site-specific neuromodulation [3][5]. While traditional AMPA receptor antagonists like perampanel act broadly, current drug discovery efforts focus on TARP-selective modulators to achieve greater regional specificity and reduce systemic side effects [5][6]. Targeting TARP gamma-4 specifically offers a potential therapeutic window for treating hyperexcitability disorders while sparing unaffected brain regions [4][6].

Other names

CACNG4Voltage-dependent calcium channel gamma-4 subunitTARP-4Neuronal voltage-gated calcium channel gamma-4 subunit

TARP gamma-4 modulates AMPA receptor function by increasing surface expression and slowing deactivation/desensitization kinetics; drugs targeting this complex typically act as non-competitive antagonists or allosteric modulators [1][3][5][7].